Cite
HARVARD Citation
Patel, J. et al. (2015). Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration‐resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance). Cancer. 121 (7), pp. 1025-1031. [Online].